CryositeASX:CTE 47 Days Inventory is 3.29 as of Dec. 2025, which is 23% below its 10-year median of 4.28. GuruFocus rates ASX:CTE with a GF Score™ of 47/100 and a GF Value™ of A$0.94 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 176 Medical Diagnostics & Research companies, Cryosite ranks better than 97.16% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Cryosite's Average Total Inventories for the
six
months ended in Dec. 2025 was A$0.06 Mil. Cryosite's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$3.19 Mil.
Hence, Cryosite's Days Inventory for the
six
months ended in Dec. 2025 was 3.29.
The historical rank and industry rank for Cryosite's Days Inventory or its related term are showing as below:
ASX:CTE'
s Days Inventory Range Over the Past 10 Years
Min: 1.86 Med: 4.28 Max: 6.73
Current: 3.45
During the past 13 years, Cryosite's highest Days Inventory was 6.73. The lowest was 1.86. And the median was 4.28.
ASX:CTE's Days Inventory is ranked better than 97.16% of 176
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.88
vs ASX:CTE: 3.45
Cryosite's Days Inventory
declined
from Dec. 2024 (4.39) to Dec. 2025 (3.29).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Cryosite's Inventory Turnover for the
six
months ended in Dec. 2025 was 55.39.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cryosite's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.01.
Cryosite (ASX:CTE) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Cryosite's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cryosite's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Cryosite Days Inventory Related Terms
Cryosite Days Inventory Historical Data
* Premium members only.
The historical data trend for Cryosite's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Cryosite's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Days Inventory distribution charts can be found below:
* The bar in red indicates where Cryosite's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a Days Inventory of 3.29 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cryosite and its competitors. This is 23% below median its historical median of 4.28. Over the past decade, Cryosite's Days Inventory has ranged from 1.86 to 6.73. According to the industry distribution chart, Cryosite ranks #5 out of 176 companies in the Medical Diagnostics & Research industry, placing it in the top 2.8%.
Is Cryosite's Days Inventory too high?
Cryosite's current Days Inventory of 3.29 is 23% below median its 10-year median of 4.28. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 6.73. The Medical Diagnostics & Research industry median Days Inventory is 68.88. Cryosite's value of 3.29 is 95.2% below this industry median. Based on the distribution chart, Cryosite ranks #5 out of 176 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cryosite has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #5 out of 176 companies for Days Inventory. This places Cryosite in the top 3% of its industry — outperforming the majority of peers. The industry median Days Inventory is 68.88. Cryosite's value of 3.29 is 95.2% below this benchmark. Historically, Cryosite's own Days Inventory has ranged from 1.86 to 6.73 over the past decade. While the company's 10-year median is 4.28 vs. the industry median of 68.88, Cryosite has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 68.88, based on 176 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current Days Inventory of 3.29 is 95.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 68.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current Days Inventory is 3.29, which is 23% below median its own 10-year median of 4.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.25 — trading 33% above its estimated fair value. The current Days Inventory is 3.29, which is 23% below median its 10-year median of 4.28 and 95.2% below the Medical Diagnostics & Research industry median of 68.88. Cryosite's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Days Inventory is 3.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.25 is trading 33% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Significantly Overvalued.
Key valuation signals for ASX:CTE:
Days Inventory: 3.29 (23% below median its 10-year median of 4.28)
GF Value™: A$0.94 vs. price of A$1.25 (33% above fair value)
Industry Position: 95.2% below the Medical Diagnostics & Research median (#5 of 176)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
47GF Score
Get the complete analysis for ASX:CTE
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
